Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Has results × 5,10-dihydro-5-methylphenazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1 Fatigue 1

Interventions

pembrolizumab 87 Cyclophosphamide 60 Paclitaxel 56 Cisplatin 54 Carboplatin 47 Gemcitabine 43 Nivolumab 40 Radiotherapy 38 Docetaxel 35 fludarabine 32 Capecitabine 31 Pemetrexed 27 Dexamethasone 26 Lenalidomide 23 fludarabine phosphate 22 Radiation 22 Doxorubicin 22 Vorinostat 21 Bevacizumab 21 Rituximab 20 Irinotecan 20 Vincristine 19 Ipilimumab 19 Temozolomide 17 Oxaliplatin 17 Azacitidine 17 atezolizumab 16 Fluorouracil 16 Etoposide 16 Cytarabine 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated

3 enrolled 7 charts

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡